Innovation Week: pushing the boundaries of AI in drug discovery

“Innovation week is about challenging and shaping the future. It’s about pushing the boundaries of AI, biology, precision medicine, data science and chemistry to develop better treatments for the patients who need them.”

At BenevolentAI, our work sits at the convergence of some of the most important trends of our time. But delivering life changing technology at pace is no easy task, especially as technology advancements accelerate faster than ever. So in this fast-moving world, we at BenevolentAI aim to ensure that while delivering on our ambitious objectives, we also support approaches to innovation that can unlock new opportunities and future growth.

Innovation Week aims to tackle this challenge, the Benevolent way. We gathered our entire team together in London to collaborate on projects and challenges that have the potential to transform our work and take it to the next level. We asked our CEO, CTO and our team to tell us about how the week played out:

Daniel Neil CTO BenevolentAI Talking about Innovation Week

Fueling continuous innovation at BenevolentAI

BenevolentAI’s CTO, Daniel Neil, discusses four approaches we use to fuel continuous innovation, including setting the criteria for success, making it okay to fail and enabling innovation at the intersections.

Read our blog →

More Posts

You Might Also Like

Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022